Infant Bacterial Therapeutics’ most advanced clinical program is the IBP-9414 project developing a preventive treatment against necrotizing enterocolitis (NEC).
- The phase II safety and tolerability study in premature infants started in 2016
- The active bacteria used in IBP-9414 is known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility
- IBP-9414 contains a co-evolved human bacterial strain derived from human breast milk
- IBP-9414 is formulated with close consideration of age-appropriateness of the vulnerable target population of preterm infants
- IBP-9414 has been granted Orphan Drug Designation for the prevention of NEC by the FDA and by the European Commission
- IBP-9414 has been granted Rare Pediatric Disease Designation for the prevention of NEC.
IBT is further pursuing a second rare disease programme IBP-1016 for the unmet medical need gastroschisis, a severe disease in infants.